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Abstract  18 
 19 
Mutations in the human kinase PINK1 (hPINK1) are associated with autosomal recessive early-onset 20 
Parkinson’s disease (PD). hPINK1 activates Parkin E3 ligase activity, involving phosphorylation of ubiquitin 21 
and the Parkin ubiquitin-like (Ubl) domain via as yet poorly understood mechanisms. hPINK1 is unusual 22 
amongst kinases due to the presence of three loop insertions of unknown function. We report the structure 23 
of Tribolium castaneum PINK1 (TcPINK1), revealing several unique extensions to the canonical protein 24 
kinase fold. The third insertion, together with autophosphorylation at residue Ser205, contributes to 25 
formation of a bowl-shaped binding site for ubiquitin. We also define a novel structural element within the 26 
second insertion that is held together by a distal loop that is critical for TcPINK1 activity. The structure of 27 
TcPINK1 explains how PD-linked mutations that lie within the kinase domain result in hPINK1 loss-of-28 
function and provides a platform for the exploration of small molecule modulators of hPINK1. 29 
 30 
 31 
  32 
 3 
Introduction  33 
 34 
Autosomal recessive inherited loss-of-function mutations in human PTEN-induced kinase 1 (hPINK1), 35 
represent the second most frequent cause of early-onset Parkinson’s disease (PD) (1). hPINK1 has been 36 
proposed to act as a master regulator of mitochondrial quality control, promoting the elimination of 37 
damaged mitochondria via autophagy known as mitophagy (2). In response to mitochondrial depolarisation, 38 
hPINK1 is activated and phosphorylates ubiquitin at Serine65 (Ser65). Ser65-phosphorylated ubiquitin then 39 
binds to the ubiquitin E3 ligase Parkin with high affinity, serving to prime Parkin for phosphorylation by 40 
hPINK1 at an equivalent Ser65 residue that lies within its N-terminal ubiquitin-like domain (Ubl) (3-6). This 41 
chain of phosphorylation events stimulates maximal activation of Parkin E3 ligase activity, resulting in 42 
ubiquitylation of multiple substrates at the outer mitochondrial membrane and represents a critical upstream 43 
step in the induction of mitophagy (2). The molecular mechanisms of hPINK1 activation and substrate 44 
recognition are poorly understood. hPINK1 is distinct from other protein kinases due to the presence of 45 
three unique insertions (Ins1, Ins2 and Ins3) within the kinase domain and a C-terminal extension (CTE) of 46 
unknown function that bears no homology to any known protein domain (Figure 1A). Nearly 30 missense 47 
and nonsense hPINK1 mutations have been reported in patients worldwide (7), located predominantly 48 
within the kinase domain or predicted to truncate the CTE. However, the molecular mechanism by which 49 
they disrupt hPINK1 catalysis and/or recognition of its physiological substrates ubiquitin and Parkin is 50 
unknown. We have previously identified a hPINK1 orthologue in Tribolium castaneum (TcPINK1), which in 51 
contrast to human hPINK1, almost entirely lacks the first kinase domain insertion (8) (Figure 1A). TcPINK1 52 
exhibits constitutive catalytic activity towards ubiquitin, Parkin and generic substrates in vitro (8, 9). 53 
Furthermore, the motor defects of Drosophila PINK1 null flies can be efficiently rescued in vivo by crossing 54 
lines that over-express TcPINK1 (8). Herein, we report the crystal structure of TcPINK1, revealing structural 55 
insights into the CTE and kinase domain loop insertions. In particular we show that the third insertion 56 
contributes to formation of a bowl-shaped binding site for ubiquitin that is critical for either TcPINK1 or 57 
hPINK1 mediated ubiquitin and Parkin Ubl phosphorylation. Furthermore, we have elaborated an important 58 
regulatory role for TcPINK1 autophosphorylation of Serine205 (Ser205), which together with the third 59 
insertion, aids in physiological substrate recognition. Overall these findings provide molecular insights into 60 
the mechanisms of hPINK1 kinase activity, ubiquitin substrate recognition, and define the molecular basis 61 
of Parkinson’s disease-causing mutations. 62 
 63 
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Results & Discussion 65 
 66 
The TcPINK1 kinase fold is decorated with unique structural features  67 
The crystal structure of a catalytically active fragment of TcPINK1 was solved and refined to 2.78 Å using 68 
E. coli expression of a cDNA construct encompassing the kinase domain and CTE (Ser150 - Asp570), and 69 
possessing mutations to reduce surface entropy (Glu527Ala and Lys528Ala), a 10 amino acid deletion in a 70 
large loop (Δ261-270), and a phospho-mimetic mutation (Ser205Glu) (Figure 1A). The crystal structure of 71 
TcPINK1 reveals core secondary structure elements of a typical protein kinase domain (10) (Figure 1B, C). 72 
As described previously (8), the N-lobe of the TcPINK1 kinase domain contains three insertions: Lys182–73 
Pro192 (Ins1), Glu221–Ala253 (Ins2), and Leu260–Met288 (Ins3) and in contrast to hPINK1, Ins1 exists as 74 
a loop remnant in TcPINK1 (Figure 1A, B). Ins2 forms a small domain containing a i-strand (222-226) and 75 
an i-helix (231-242) followed by a loop (243-253). Ins3 is disordered and is not included in the final model 76 
(Figure 1B, C). Finally, the majority of the TcPINK1 CTE (Ala487–Leu556) is -helical in nature (Figure 1B, 77 
C), and rather than forming a separate domain, is tightly packed on the E, G and H -helices of the C-lobe 78 
of the kinase domain (3747 Å2 buried surface area), supporting previous data on the importance of this 79 
region for catalysis (8). A DALI structure similarity search revealed that Ins2 and the CTE structural 80 
elements are unique to TcPINK1 and not found in the almost thousand kinase structures solved to date. 81 
Although TcPINK1 was crystallised without ATP, the kinase domain appears to adopt an active, closed 82 
conformation, based on the positioning of the αC helix, activation segment conformation, and the “in” 83 
position of the DFG motif (11-13) (Figure 1B). A model of the ATP was included by superposition with the 84 
conformationally similar cAMP dependent protein kinase-ATP complex (RMSD 3.2 Å on 252 equivalent C 85 
atoms). This suggested that residues Ala194, Lys196, Leu344, Tyr297 and Glu217 are critical for ATP 86 
binding (Figure 1-figure supplement 1A). In agreement with this, biochemical analysis revealed that the 87 
Ala194Asp, Lys196Ala and Glu217Lys TcPINK1 mutants prevented phosphorylation of its physiological 88 
substrates, ubiquitin and the Parkin Ubl domain (Figure 1D-figure supplement 1B). Furthermore, inspection 89 
of the structure indicates that the conformation of residues forming two conserved hydrophobic networks 90 
(the “R-spine” comprising residues Ile253, Val219, Phe360, His335 and Asp410, and the “C-spine” 91 
residues Val176, Leu301, Leu343, Leu344, Leu345, ILe421 and Ile417) is compatible with an active 92 
conformation (14, 15).  93 
 94 
Ins3 forms the ubiquitin binding pocket 95 
hPINK1-dependent phosphorylation of Ser65 on ubiquitin and the Ubl domain of Parkin is critical for 96 
maximal Parkin activation (16, 17). However, the regions of hPINK1 that recognize and bind its substrates 97 
remain unknown. Via DALI structure similarity search, we identified the LIM kinase-cofilin complex (18) as 98 
being conformationally similar to TcPINK1 (RMSD 2.8 Å on 298 equivalenced C atoms). Using the 99 
phosphopeptide in this complex as an anchor (Figure 2A), we superimposed phospho-Ser65 of ubiquitin 100 
onto the TcPINK1 active site, resulting in a model of the TcPINK1-ubiquitin complex, free of steric clashes 101 
(Figure 2B). Using this model, we explored the key structural elements in TcPINK1 that may contribute to 102 
recognition of ubiquitin. Although Ins3 in the TcPINK1 kinase domain is mostly disordered and could not be 103 
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built as part of the structure, its predicted location places it proximal to the ubiquitin in the model of the 104 
complex and therefore we hypothesized that it is likely to contribute a critical role towards substrate 105 
recognition and binding. To test this, we deleted 10 residues (residues 261-270, equivalent to the deletion 106 
used in the crystallisation construct) of Ins3 and measured TcPINK1 catalytic activity using multiple 107 
physiological readouts, including TcPINK1 catalysed phosphorylation of ubiquitin and the Parkin Ubl 108 
domain, and transphosphorylation of a kinase-inactive (D359A) TcPINK1 fragment (residues 125-570; His-109 
SUMO cleaved) (Figure 2C, D-figure supplement 1A). Strikingly, deletion of Ins3 resulted in complete loss 110 
of ubiquitin or Parkin Ubl phosphorylation, while preserving transphosphorylation activity towards kinase-111 
inactive TcPINK1 (Figure 2C, D-figure supplement 1A). We also found that mutation of key residues 112 
Leu371, Tyr375, Lys382 & Lys435 within the canonical substrate binding pocket of kinases resulted in loss 113 
of activity against ubiquitin (Figure 2B-figure supplement 1B).  114 
We have previously identified multiple autophosphorylation sites for TcPINK1 by mass 115 
spectrometry, including Ser205 (equivalent to Ser228 in hPINK1) and Ser207 (equivalent to Ser230 in 116 
hPINK1) (8). Ser207 phosphorylation was also observed in the crystal structure (Figure 2B). Inspection of 117 
the structure revealed that Glu205 (the phosphomimetic of Ser205) lies only 4 Å away from the tail 118 
(Asn287) of the disordered Ins3 (Figure 2B). We therefore hypothesized that autophosphorylation of 119 
Ser205 may influence and/or contribute to ubiquitin recognition and binding mediated by Ins3. Therefore, to 120 
test the effect of Ser205 phosphorylation in substrate recognition, we performed parallel assays with 121 
ubiquitin, Parkin Ubl domain and transphosphorylation of kinase-inactive TcPINK1 as performed for the 122 
Ins3 deletion. Critically Ser205Ala, but not Ser207Ala, prevented ubiquitin and Parkin Ubl phosphorylation 123 
while preserving transphosphorylation activity towards kinase-inactive TcPINK1 (Figure 2C, D-figure 124 
supplement 1A). Overall these findings indicate that Ins3, unique to the PINK1 kinases, together with 125 
autophosphorylation at Ser205, is critical for ubiquitin and Parkin Ubl phosphorylation and may form part of 126 
the ubiquitin/Ubl fold recognition pocket.  127 
 128 
Role of novel regulatory features of TcPINK1 catalysis  129 
Multiple lines of evidence suggest that hPINK1 is autoinhibited under basal conditions, including lack of 130 
significant activity of hPINK1 in vitro (8) and the detection of robust activity of hPINK1 in cells only under 131 
conditions of mitochondrial depolarization triggering hPINK1 activation via an unknown mechanism (3). In 132 
contrast to hPINK1, insect orthologues isolated from Drosophila melanogaster, Pediculus humanus 133 
corporis and Tribolium castaneum exhibit constitutive catalytic activity in vitro (8, 16). Since the TcPINK1 134 
kinase domain adopts an active conformation in our crystal structure, we sought to exploit this knowledge 135 
to probe possible mechanisms of hPINK1 activation. Activation loop phosphorylation is the most common 136 
mechanism of protein kinase activation (10), with phosphorylation stabilising the active conformation via 137 
electrostatic interaction between the phospho-serine/threonine residue and a basic pocket consisting of the 138 
arginine in the HRD motif (13). Previous mass spectrometry analysis of TcPINK1 did not identify activation 139 
loop phosphorylation, and furthermore, alanine mutation of a candidate T-loop phosphorylation site residue, 140 
Ser377, did not impair TcPINK1 catalytic activity (8). Consistent with this we do not observe 141 
phosphorylation of Ser377 in the TcPINK1 structure and furthermore, Ser377 is located too distant (12.2 Å) 142 
from Arg336 of the HRD motif to form an electrostatic interaction (Figure 3A). Instead the TcPINK1 143 
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structure reveals that a highly conserved aspartate (Asp381) within the activation loop, an arginine residue 144 
(Arg336) of the HRD motif and an arginine residue (Arg216) in the αC-helix, form an equivalent interaction 145 
(Figure 3A), which is further stabilized via interaction with basic residues (Lys212 on the αC-helix; Arg240 146 
and Arg241 in Ins2) and another conserved aspartate (Asp366). To explore which residues were important 147 
for TcPINK1 catalysed phosphorylation of its substrates we investigated point mutants of residues lying 148 
within this region. The Asp366Ala TcPINK1 mutant was unstable under our expression conditions and was 149 
not assessed. Importantly our data revealed that mutants in this region, particularly the Asp381Ala and 150 
Arg240Ala mutants, were associated with a significant reduction in TcPINK1 catalytic kinase activity 151 
towards ubiquitin (Figure 3B). Although Asp381 & Asp366 are conserved in hPINK1, Lys212 and Arg216 152 
form a basic patch on the αC-helix that is conserved among the insect orthologues but not in hPINK1, 153 
where the equivalent residues are Asn235 and Gln239. Furthermore, Arg240 & Arg241 of TcPINK1 are 154 
replaced by Gly264 & Pro265 in hPINK1, respectively (Figure 3-figure supplement 1A). We hypothesized 155 
that these differences in basic residues between TcPINK1 and hPINK1 could explain the lack of 156 
recombinant hPINK1 activity. To test this, we generated a mutant of hPINK1 incorporating 157 
Asn235Lys/Gln239Arg/Gly264Arg/Pro265Arg substitutions, however this did not lead to any significant 158 
enhancement in hPINK1 activity (data not shown).   159 
Inspection of the TcPINK1 structure suggests another potential regulatory mechanism of activation 160 
through interaction of Ins2 with the αC-helix (1120 Å2 buried surface area) (Figure 3C). This interaction is 161 
reminiscent of the activation mechanism of cyclin dependent kinases (CDKs), whereby intermolecular 162 
stabilization of the CDK αC-helix occurs due to interactions with the cyclin α5-helix (Figure 3C) (19). The 163 
TcPINK1 αi-helix (residues 231-242) of Ins2 (residues 221-253) occupies a similar position to cyclin, 164 
inducing a displacement of the αC-helix and allowing formation of the key salt bridge between the 165 
conserved Glu217 on the αC-helix and the conserved Lys196 on the N-lobe, maintaining the kinase in an 166 
active conformation (Figure 3C). Akin to the intermolecular CDK-cyclin interaction, the TcPINK1 αC-helix-167 
αi-helix intramolecular interface also consists of hydrophobic interactions (Figure 3C). Whilst the overall 168 
conservation of Ins2 (residues 221-253) is low, the C-terminal/distal region (243-253) of Ins2 remains highly 169 
conserved (Figure 3-figure supplement 1A), forming a loop (Ins2 loop) which tethers the proximal region of 170 
Ins2 (i-strand & αi-helix) with the rest of the C-lobe mediated by interactions between His247 & Asn249 of 171 
Ins2 and Ser545 of CTE & Gln320 of the C-lobe, respectively. Furthermore, a hydrophobic core is formed 172 
between Leu244 and Ile250 of Ins2 with Phe360 of the “DFG motif” and Ile357 (Figure 3C). Interestingly, 173 
deletion of the αi-helix (residues 231-242) alone or in combination with the i-strand (residues 222-242) 174 
region of Ins2 does not affect the catalytic activity of TcPINK1. However, deletion of the Ins2 loop (residues 175 
243-253) abolishes the kinase activity of TcPINK1 (Figure 3D-figure supplement 1B). Therefore, our 176 
analysis suggests a critical role for the Ins2 loop (243-253) as an anchor, to maintaining the kinase domain 177 
in an active state, although the function of the proximal region of Ins2 (222-242) remains to be fully 178 
elucidated.  179 
 180 
Translating structural insights to hPINK1  181 
Sequence alignment of hPINK1 and TcPINK1 reveals an overall high degree of conservation with the 182 
exception of the relative absence of Ins1 in TcPINK1 (Figure 4-figure supplement 1). Therefore, we next 183 
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explored the structural and functional conservation between insect and human PINK1 in cells expressing 184 
hPINK1 whose kinase activity can be stimulated by carbonyl cyanide m-cholorophenylhydrazone (CCCP) 185 
that induces mitochondrial depolarization (9). We transiently expressed wild type hPINK1 or mutants of key 186 
ATP-binding residues predicted from the TcPINK1 structure (Figure 1D-figure supplement 1A) into HeLa 187 
hPINK1 knockout cells generated by CRISPR/Cas9 technology (20). Cells were treated with 10 M CCCP 188 
or DMSO for 3 h and extracts immunoblotted with phospho-specific antibodies raised against hPINK1 189 
substrates Ser65 Parkin and Ser65 ubiquitin. Consistent with our analysis of TcPINK1 (Figure 1D), we 190 
found that Parkin and ubiquitin phosphorylation was abolished in cells expressing mutant A217D, K219A, 191 
E240K and L369P forms of hPINK1 upon CCCP stimulation (Figure 4A). This indicates that the ATP-192 
binding pocket is well conserved between TcPINK1 and hPINK1. We next explored whether Ins3, which is 193 
well conserved between TcPINK1 and higher species, is critical for ubiquitin and Parkin Ubl recognition by 194 
hPINK1. Consistent with TcPINK1, we observed abrogation of phosphorylation of ubiquitin and Parkin in 195 
cells expressing hPINK1 harbouring a deletion of Ins3 (285-294 – corresponding to deletion in TcPINK1 196 
261-270) in striking contrast to cells expressing hPINK1 containing a deletion in Ins1 (180-209) or a 197 
deletion in the proximal region of Ins2 (245-265 - corresponding to i-strand & αi-helix of TcPINK1). 198 
Overall these findings indicate that hPINK1 and TcPINK1 share similar mechanisms for substrate 199 
recognition and kinase activity, suggesting that the TcPINK1 structure will provide an important framework 200 
to direct future studies aimed at structural studies of the hPINK1 enzyme.  201 
 202 
Molecular mechanisms of inactivating Parkinsonism mutations in hPINK1 203 
Mutations in hPINK1 are a leading cause of familial early-onset PD and whilst previous studies have 204 
demonstrated that mutations disrupt hPINK1-dependent activity and mitophagy in cells (2, 7), very little is 205 
known about how these impact hPINK1 structure. Of the approximately thirty reported homozygous or 206 
compound heterozygous pathogenic mutations (7), twenty are conserved in TcPINK1 (Supplementary file 207 
1). Mapping of these pathogenic mutations onto the structure of TcPINK1 (Figure 5-supplementary file 1), 208 
reveals that they cluster within functionally distinct regions of hPINK1. A major group of PD-associated 209 
mutations lie within the ATP binding pocket including Ala217Asp, Glu240Lys, Ala244Gly and Leu369Pro 210 
and perturb interactions with ATP. A second group of mutations that lie in the catalytic motif or activation 211 
loop include Gly386Ala, Pro416Arg/Leu and Glu417Gly (Figure 5A, C) result in catalytically inactive 212 
hPINK1 (7). The His271Gln mutation lies within the critical distal Ins2 loop of hPINK1 (Figure 5A, C), that 213 
anchors the proximal Ins2 to the C-lobe (Figure 3D), and has previously been found to abolish catalytic 214 
activity in vitro (8) as well as hPINK1 activity in cells (21). In contrast, the Gly309Asp (G309D) PD mutation 215 
located within Ins3 (Figure 2) would be predicted to perturb hPINK1 and substrate (ubiquitin/Ubl domain of 216 
Parkin) interaction as our analysis suggests that Ins3 is required for ubiquitin phosphorylation (Figure 2C-217 
figure supplement 1A). Consistent with this, a previous study showed that the G309D hPINK1 mutant fails 218 
to phosphorylate Parkin Ubl in cells (22) whereas the equivalent TcPINK1 G285D mutant continues to 219 
exhibit catalytic activity towards generic and peptide substrates in vitro (8). The remainder of mutations 220 
mainly affect residues critical for structural integrity of hPINK1. In particular, the CTE of TcPINK1 forms a 221 
hydrophobic core against the E, G and H helices of the C-lobe (Fig. 5B), and a cluster of PD mutations in 222 
 8 
hPINK1 including Leu539Phe, Leu347Pro and Leu489Pro located in this vicinity suggest the importance of 223 
this hydrophobic core (Figure 5B). Attempts to purify soluble protein for a number of point mutants targeting 224 
this hydrophobic interface were unsuccessful, underscoring the importance of this hydrophobic core which 225 
explains loss of kinase activity of TcPINK1 upon CTE deletion in previous studies (8). Although it has 226 
previously been suggested that CTE may be important for dimerization [23], we did not find evidence for a 227 
functional dimer in our TcPINK1 purification procedures or crystal structure. 228 
 229 
Overall the TcPINK1 structure provides molecular insights into the structural regulation of hPINK1 and in 230 
particular defines functional roles for its unique loop insertions in ubiquitin substrate recognition and 231 
catalytic activity. The structure provides clarity on the impact of loss of function disease-associated 232 
mutations, which may stimulate future drug discovery efforts for both familial and idiopathic PD.  233 
 234 
 235 
 236 
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Figure legends  260 
 261 
Figure 1: Overall structure of TcPINK1  262 
A. Domain architecture of TcPINK1 showing kinase domain (150-486); location of Ins2, Ins3, catalytic 263 
motif (HRD) and activation loop motifs (DFG; APE) and CTE (487-570). The location of hPINK1 264 
Ins1, which is largely absent in TcPINK1, is indicated. CTE, C-terminal extension; Ins, insertion. 265 
Created with IBS (24). The boundaries of the crystallisation construct with the mutations introduced 266 
is also shown, lower panel. 267 
B. Overall structure of TcPINK1 showing the canonical N-lobe & C-lobe (grey). Catalytic and activation 268 
loop motifs are shown in magenta sticks and Mg2+ is shown as a black sphere. Ins2, Ins3 and CTE 269 
of TcPINK1 are coloured as in Fig 1A; disordered regions of PINK1 are shown in dashed line; Ins1 270 
of hPINK1 is also shown as part of disordered loop in TcPINK1. 271 
C. Topology diagram of the TcPINK1 structure. Core kinase domain secondary structure elements are 272 
shown in grey and indicated with numbers (β-sheet) and letters (α-helices) according to the 273 
nomenclature in (10). Non-canonical secondary structure elements (CTE, C-terminal extension; Ins, 274 
insertion) are indicated with Roman numerals for Ins2 (cyan), Ins3 (green) and numbering for CTE 275 
(blue). Created with TopDraw (25). 276 
D. Ubiquitin phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant (KI), 277 
and ATP-binding pocket mutations A194D, K196A and E217K. 2 μg of indicated enzyme was 278 
incubated with 2 μM ubiquitin (K63-linked tetraubiquitin) and [γ-32P] ATP for 10 min. Gels were 279 
analysed by Coomassie staining (lower panel) and [γ-32P] incorporation visualised by 280 
autoradiography (upper panel) followed by Cerenkov counting of substrate bands for quantification 281 
(right panel).  282 
  283 
 284 
Figure 2: Identification of the PINK1 substrate binding bowl 285 
A. Crystal structure of the LIM kinase substrate complex (pdb id: 5HVK, 18) showing LIM kinase 286 
(coloured as TcPINK1 in Fig. 1B) and bound substrate cofilin (yellow) with Ser3 (yellow stick) poised 287 
in acceptor position. 288 
B. Ubiquitin (yellow) was modelled in TcPINK1 (coloured as in Fig. 1B) by superposing Ser3 of cofilin 289 
with Ser65 (shown as sticks) of ubiquitin after superposing the TcPINK1 and LIM kinase domains; 290 
disordered Ins3 is marked by dashed green line; 2Fo-Fc map, contoured at 1.5, corresponding to 291 
phosphorylated Ser207 region is shown highlighting the Glu205 position in respect to Asn287 (tail of 292 
disordered Ins3), inset.  293 
C. Ubiquitin phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant (KI), 294 
insertion 3 deletion mutant (Δ261-270), S205A and/or S207A mutants in the autophosphorylation 295 
sites. 2 µM ubiquitin (K63-linked tetraubiquitin) was used as substrate; assay conditions were 296 
similar to Figure 1D. Gels were analysed by Coomassie staining (lower panel) and [γ-32P] 297 
incorporation visualised by autoradiography (middle panel) followed by Cerenkov counting of 298 
substrate bands for quantification (upper panel).  299 
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D. TcPINK1 transphosphorylation assay with full-length TcPINK1 (WT) or various mutants as in Figure 300 
2C. 2µM of kinase inactive TcPINK1 (125-end) was used as substrate; assay conditions were 301 
similar to Figure 1D. Gels were analysed by Coomassie staining (lower panel) and [γ-32P] 302 
incorporation visualised by autoradiography (middle panel) followed by Cerenkov counting of 303 
substrate bands for quantification (upper panel). 304 
 305 
Figure 3: Ins2 of TcPINK1 adopts a unique conformation 306 
A. Close up view of active site of TcPINK1 (coloured as in Fig. 1B) showing key ionic interactions 307 
involving Asp381 of the activation loop with Arg336 of the HRD motif and Arg216 of the C helix; 308 
and Asp366 with Lys212 of the C helix and Arg240 of Ins2.    309 
B. Ubiquitin phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant (KI), 310 
D381A, R216A, K212A and R240A mutants. 2 µM of Ubiquitin (K63-linked tetraubiquitin) was used 311 
as substrate; conditions were similar to Figure 1D. Gels were analysed by Coomassie staining 312 
(lower panel) and [γ-32P] incorporation visualised by autoradiography (upper panel) followed by 313 
Cerenkov counting of substrate bands for quantification (right panel). 314 
C. Structural comparison of TcPINK1 and the CDK-Cyclin complex (pdb id: 5IF1) showing 315 
intramolecular interactions between Ins2 (cyan) and C helix (grey) of TcPINK1 that resemble the 316 
intermolecular interactions between CDK (grey) and Cyclin (cyan). The salt bridge between Glu and 317 
Lys (shown in sticks) for kinase activation is represented by a dashed line. Interactions between the 318 
C-lobe and the distal Ins2 loop are highlighted (Inset).  319 
D. Ubiquitin phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant (KI) 320 
and TcPINK1 Ins2 mutants with i-strand & αi-helix deletion (∆222-242), αi-helix deletion (∆231-321 
242), or distal loop deletion (∆243-253). 2 µM of Ubiquitin (K63-linked tetraubiquitin) was used as 322 
substrate, conditions were similar to Figure 1D. Gels were analysed by Coomassie staining (lower 323 
panel) and [γ-32P] incorporation visualised by autoradiography (middle panel) followed by Cerenkov 324 
counting of substrate bands for quantification (upper panel). 325 
 326 
Figure 4: Conservation of ATP & substrate binding mechanism in hPINK1  327 
 328 
A. hPINK1 knock out HeLa cells transiently co-expressing WT human Parkin and 3xFLAG tagged 329 
hPINK1 WT, KI or hPINK1 ATP-binding mutants A217D, K219A, E240K, L369P. A217, K219, E240 330 
& L369 correspond to A194, K196, E217 & L344 of TcPINK1, respectively. Cells were stimulated 331 
with 10 M CCCP or DMSO for 3 h. Lysates were subjected to immunoblotting as follows: pSer65 332 
Parkin (anti-phospho-Parkin); Parkin (anti-Parkin), pSer65 ubiquitin (anti-phospho-ubiquitin), 333 
hPINK1 (anti-FLAG), OPA1 (anti-OPA1) and GAPDH (anti-GAPDH). 334 
 335 
B. hPINK1 knock out HeLa cells transiently co-expressing WT human Parkin and 3xFLAG tagged 336 
hPINK1 WT, KI or hPINK1 Ins mutants ∆Ins1 (180-209 deletion), ∆Ins2 (245-265 deletion), ∆Ins3 337 
(285-294). Cells were stimulated with 10 M CCCP or DMSO for 3 h. Lysates were subjected to 338 
immunoblotting as follows: pSer65 Parkin (anti-phospho-Parkin); Parkin (anti-Parkin), pSer65 339 
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ubiquitin (anti-phospho-ubiquitin), hPINK1 (anti-FLAG), OPA1 (anti-OPA1) and GAPDH (anti-340 
GAPDH).  341 
 342 
Figure 5: Spatial map of Parkinson’s disease (PD) linked mutations within hPINK1  343 
A. Mapping of PD mutations onto the TcPINK1 structure (coloured as in Fig. 1B). Pathogenic hPINK1 344 
disease mutant residues are shown in red sticks; disease mutants in the disordered region 345 
(represented by dashed line) of Ins3 are labelled in red characters.  346 
B. Interface of the CTE and C-lobe of TcPINK1 showing the hydrophobic core (shown in grey or blue) 347 
of the TcPINK1 kinase domain. hPINK1 PD mutations in the vicinity of the hydrophobic core are 348 
shown in red sticks.  349 
C. Location of hPINK1 PD mutations (marked with red lines) on the primary TcPINK1 sequence. 350 
hPINK1 mutations are shown in parenthesis. 351 
  352 
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Materials & Methods  353 
 354 
Protein expression, purification and crystallography 355 
BL21 codon plus (DES) RIPL (Stratagene) were transformed with pET15 6HIS SUMO TcPINK1S150-D570 ΔI261-356 
L270 S205E E527A K528A (available from MRC PPU Reagents and Services: http://mrcppureagents.dundee.ac.uk). 357 
For overexpression, 1 L of Terrific broth (TB) medium was inoculated with 10 ml of overnight culture. 358 
Cultures were propagated in a shaking incubator (Infors HT) at 37 °C and 200 rpm until OD600 ~0.6 - 0.8. 359 
Temperature was then reduced to 16 °C upon which cultures were supplemented with 100 µM IPTG and 360 
grown overnight. Cells were harvested by centrifugation at 4000 rpm for 25 min (Beckman coulter J6-Mi 361 
centrifuge). Cell pellets were carefully resuspended in ~4  cell volume of lysis buffer (50 mM EPPS pH 8.6, 362 
500 mM NaCl, 5% glycerol, 3% sucrose, 5 mM imidazole) at 12 oC by gentle shaking (150 rpm). Before 363 
lysis, 0.5 mM TCEP pH 7.5 (from Apollo Scientific), 0.1 mM Pefabloc (Sigma Aldrich), and 10 µM Leupeptin 364 
(Apollo Scientific) were added to the mixture. Cells were then lysed by sonication (6 x10 second pulses at 365 
10 second intervals, 45% amplitude) and to remove the cell debris, the cell lysates were centrifuged at 366 
28,000 rpm for 25 min at 4 °C (Beckman Avanti J-30 I centrifuge).  367 
For protein purification, the supernatant was incubated with Nickel sepharose beads previously equilibrated 368 
with 10 CV binding buffer (50 mM EPPS pH 8.6, 500 mM NaCl, 5% glycerol, 3% sucrose, 5 mM imidazole, 369 
0.5mM TCEP, pH 7.5) for 1 h at 4 oC on a roller. Thereafter, the beads were collected by filtration and 370 
washed thoroughly (800 ml -1 L) with binding buffer containing 30 mM imidazole. The protein was then 371 
eluted from the beads using the elution buffer (50 mM EPPS pH 8.6, 500 mM NaCl, 5% glycerol, 3% 372 
sucrose, 400 mM imidazole, 0.5 mM TCEP, pH 7.5). The eluted protein was mixed with His-SENP1 373 
protease (1 mg of His-SENP1 per 25 mg of TcPINK1) to cleave off the SUMO tag and dialyzed into 30 mM 374 
HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 3% sucrose, 0.25 mM TCEP, pH 7.5 at 4 oC overnight (using 375 
3.5 kDa SnakeSkin dialysis tubing; Thermo Fisher).  The dialyzed mixture was subjected to negative pull 376 
down using Nickel sepharose resin to remove the His-SUMO and TcPINK1 was concentrated to ~5 ml. 377 
Reductive methylation of lysine residues was then performed (as described in Hampton Research 378 
Protocols) before loading onto a gel filtration column (HiLoad Superdex 16/600, GE Healthcare), previously 379 
equilibrated with the gel filtration buffer (25 mM HEPES, pH 7.5, 300 mM NaCl, 5% glycerol, 3% sucrose, 2 380 
mM TCEP, pH 7.5). Following gel filtration, methylated TcPINK1 was concentrated to 9 mg/ml flash frozen 381 
in liquid nitrogen and stored at -80 oC for further use. For overexpression, purification and methylation of 382 
selenomethionine (SeMet) TcPINK1 derivatives, an identical protocol was used (using MD12-500 kit from 383 
Molecular Dimensions to incorporate selenomethionine). Native and selenomethionine derivatised TcPINK1 384 
was crystallised using 5 mg/ml of protein mixing with 200 mM MgCl2, 100 mM HEPES pH 7.0, 20% PEG 385 
6000 and 200 mM MgCl2 or 100 mM HEPES pH 7.5, 25% PEG 3350 and 200 mM MgCl2, respectively, 386 
under vapor diffusion sitting drop method. Crystals were flash frozen using 20% of glycerol with mother 387 
liquor. Data were collected at ESRF, with a SeMet anomalous data set collected at the selenium absorption 388 
edge. Selenomethionine-incorporated and native crystals diffracted to 3.4 Å and 2.8 Å, respectively. Data 389 
were processed using XDS (26) and AIMLESS (27). SAD phasing was performed on the anomalous data 390 
set using CRANK2 in the CCP4 program suite. Phases were improved by iterative cycles of manual model 391 
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building and refinement using Coot (28) and Refmac (27), respectively (Table 1). Ramachandran values 392 
were calculated using MolProbity (29) with 94% of residues in the most favored regions.  393 
 394 
Protein purification from E. coli for kinase assays 395 
Full length wild-type and mutant TcPINK1 were expressed in E. coli (BL21-codonplus) as maltose binding 396 
protein fusion proteins. Cells were grown at 37 °C, induced with 250 μM IPTG at OD600 0.6 and were further 397 
grown at 16 °C for 16 h. Cells were pelleted at 4000 r.p.m., and then lysed by sonication in lysis buffer. 398 
Lysates were clarified by centrifugation at 30 000 g for 30 min at 4 °C followed by incubation with 1 ml per 399 
litre of culture of amylose resin for 1.5 h at 4 °C. The resin was washed thoroughly in wash buffer, then 400 
equilibration buffer, and proteins were then eluted. Proteins were dialysed overnight at 4°C into storage 401 
buffer, snap-frozen and stored at −80 °C until use. Kinase assay substrates (ubiquitin, Parkin Ubl, and 402 
TcPINK1 125-end D359A) were expressed as 6His-SUMO fusion proteins using the same conditions. 403 
Cleared lysate was incubated with 1 ml Ni2+-NTA resin/litre of culture for 1.5 h at 4 °C. The resin was 404 
washed thoroughly in wash buffer, then equilibration buffer, and proteins were then eluted. Proteins were 405 
dialysed overnight at 4 °C into storage buffer. 6His-SUMO tags were cleaved by the addition of SENP1 at a 406 
ratio of 1:10 protease:tagged-protein. Tag-cleaved protein was purified by thorough incubation with Ni2+-407 
NTA resin, and then snap-frozen and stored at −80 °C until further use.  408 
  409 
Kinase assays 410 
Reactions were set up in a volume of 40 μl, using 2 μg/30 ng of E. coli-expressed TcPINK1 and 2 μM of 411 
substrate, in 50 mM Tris–HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT and 0.1 mM [γ-
32P] ATP 412 
(approx. 500 cpm pmol−1). Assays were incubated at 30 °C with shaking at 1050 r.p.m. and terminated after 413 
10 min by addition of SDS sample loading buffer. The reaction mixtures were then resolved by SDS–414 
PAGE. Proteins were detected by Coomassie staining, and gels were imaged using an Epson scanner and 415 
dried completely using a gel dryer (Bio-Rad). Incorporation of [γ-32P] ATP into substrates was analysed by 416 
autoradiography using Amersham hyperfilm. Quantification of [γ-32P] incorporation into substrates was 417 
performed by Cerenkov counting of respective SDS-PAGE gel bands. 418 
 419 
Buffers for E. coli protein purification for activity assays 420 
TcPINK1 and indicated mutants were expressed as maltose-binding protein fusion proteins: lysis buffer 421 
contained 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5% (v/v) glycerol, 1% (v/v) 422 
Triton X-100, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF. Wash buffer contained 423 
50 mM Tris–HCl (pH 7.5), 500 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) 424 
2-mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF. Equilibration buffer contained 50 mM Tris–HCl 425 
(pH 7.5), 150 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-426 
mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF. Elution buffer was equilibration buffer with the 427 
addition of 12 mM maltose. Storage buffer was equilibration buffer with the addition of 0.27 M sucrose, and 428 
glycerol–PMSF and benzamidine were omitted. 429 
 430 
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Ubiquitin K63 tetramer was expressed as previously described (30). Lysis buffer contained 50 mM Tris–HCl 431 
(pH 7.5), 150 mM NaCl, 5% (v/v) glycerol, 20 mM imidazole, 1% (v/v) Triton X-100, 0.1% (v/v) 2-432 
mercaptoethanol, 1 mM benzamidine and 0.1 mM PMSF. Wash buffer contained 50 mM Tris–HCl (pH 7.5), 433 
500 mM NaCl, 5% (v/v) glycerol, 20 mM imidazole, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 1 434 
mM benzamidine and 0.1 mM PMSF. Equilibration buffer contained 50 mM Tris–HCl (pH 7.5), 150 mM 435 
NaCl, 5% (v/v) glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM 436 
PMSF. Elution buffer was equilibration buffer with the addition of 200 mM imidazole. Storage buffer was 437 
equilibration buffer with the addition of 0.27 M sucrose, and glycerol–PMSF and benzamidine were omitted. 438 
 439 
Cell culture 440 
HeLa hPINK1 knockout cell lines were obtained from Richard Youle (NIH) and were cultured using DMEM 441 
(Dulbecco's modified Eagle's medium) supplemented with 10% FBS (foetal bovine serum), 2 mM L-442 
glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin. Cells were transiently transfected with WT 443 
Parkin and 3xFLAG tagged PINK1 using polyethylene method. Mitochondria were uncoupled using 10 μM 444 
CCCP (Sigma) dissolved in DMSO for 3 h. 1% Triton solubilized lysates were resolved on SDS-PAGE, and 445 
wet transferred onto nitrocellulose membranes. Membranes were blocked with 5% BSA followed by 446 
overnight incubation with the indicated antibodies in 5% BSA or milk in TBST at 4 degrees. Membranes 447 
were incubated with HRP conjugated secondary antibodies diluted (1: 10,000) in 1X TBST with 5% BSA for 448 
1 h at room temperature followed by exposure with ECL, pSer65 Parkin membranes were incubated with 449 
secondary antibodies conjugated with LI-COR IRDye® at 1:10,000 dilution in 1X TBST with 5% BSA. List of 450 
antibodies used in the present study are mentioned in Supplementary file-2. 451 
 452 
 453 
 454 
 455 
  456 
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Legends to figure supplements 457 
 458 
Figure 1-figure supplement 1: Mutations in the TcPINK1 ATP binding pocket result in loss of kinase 459 
activity.  460 
A. ATP (orange sticks) was modeled in the TcPINK1 structure using superposed coordinates of cAMP-461 
dependent protein kinase in complex with ATP (pdb id:1ATP), TcPINK1 residues involving 462 
interactions with ATP are shown in grey sticks, remaining features of TcPINK1 are colored as in 463 
Figure 1B. 464 
B. Parkin Ubl phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant 465 
(KI), and ATP-binding pocket mutants A194D, K196A and E217K. 30 ng of indicated enzyme was 466 
incubated in the presence of 2 μM Ubl domain of Parkin (1-76) and [y-32P] ATP for 10 min. 467 
Reactions were terminated by addition of SDS sample buffer and separated by SDS-PAGE. [γ-32P] 468 
incorporation visualised by autoradiography (upper panel), followed by Cerenkov counting of 469 
substrate bands for quantification (top panel), Western blot against TcPINK1 (lower panel) and 470 
Coomassie stained gels showing UBL (middle panel) are used as loading control. 471 
 472 
Figure 2-figure supplement 1: TcPINK1 Mutations in Ins3, autophosphorylation site & canonical 473 
substrate binding region result in loss of activity.  474 
A. Parkin Ubl phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant 475 
(KI), Ins3 deletion (∆261-270), S205A, S207A and S205A/S207A. 30 ng of indicated enzyme was 476 
incubated in the presence of 2 μM Ubl domain of Parkin (1-76) and [y-32P] ATP for 10 min. 477 
Reactions were terminated by addition of SDS sample buffer and separated by SDS-PAGE. [γ-32P] 478 
incorporation visualised by autoradiography (upper panel), followed by Cerenkov counting of 479 
substrate bands for quantification (top panel), Western blot against TcPINK1 (lower panel) and 480 
Coomassie stained gels showing Ubl (middle panel) are used as loading control. 481 
B. Ubiquitin phosphorylation assay with TcPINK1 (WT), kinase-inactive D359A mutant (KI), and 482 
canonical substrate-binding mutants L371A, Y375A, K382A, and K435A. 2 μg of indicated enzyme 483 
was incubated in the presence of 2 μM ubiquitin (K63-linked tetraubiquitin), and [γ32-P] ATP for 10 484 
min. Reactions were terminated by addition of SDS sample buffer and separated by SDS-PAGE. 485 
Gels were analysed by Coomassie staining (lower panel) and [γ-32P] incorporation visualised by 486 
autoradiography (middle panel), followed by Cerenkov counting of substrate bands for quantification 487 
(upper panel). 488 
 489 
Figure 3-figure supplement 1: High conservation and functionally important role of C-terminal distal 490 
loop of Ins2 in TcPINK1 activity 491 
A. Multiple sequence alignment of PINK1 kinases showing conservation of important residues/regions 492 
highlighted in Figure 3. Secondary structure elements are included based on TcPINK1 structure; 493 
elements numbering is consistent with Fig. 1C. Numbering of residues is according to TcPINK1 494 
sequence; marked arrows represents residues highlighted in catalytic cleft of TcPINK1 in Figure 3. 495 
Two different regions in the alignment are separated by dashed line. 496 
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B. Parkin Ubl phosphorylation assay with full-length TcPINK1 (WT), kinase-inactive D359A mutant 497 
(KI), PINK1 Ins2 mutants with i-strand & αi-helix deletion (∆222-242) or αi-helix deletion (∆231-498 
242) or distal loop deletion (∆243-253) in Ins2. Ubl was used as substrate under the same 499 
conditions as Figure 1-figure supplement 1. 500 
 501 
Figure 4-figure supplement 1: Sequence alignment of TcPINK1 and hPINK1. Secondary structure 502 
elements are included based on TcPINK1 structure. Elements numbering is consistent with Figure 1C; 503 
numbering of residues is according to the TcPINK1 sequence. ATP binding residues shown in Figure 1 are 504 
marked with *. Location of loop insertions are coloured according to Figure 1. 505 
 506 
Supplementary file 1: List ofhPINK1 PD mutations conserved in TcPINK1 and their predicted impact 507 
 508 
Supplementary file 2: List of Antibodies used and their source 509 
 510 
 511 
 512 
  513 
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 514 
Table 1: Diffraction data and refinement statistics.  515 
 TcPINK1 (Native) 
Data collection  
Space group P1 21 1 
  
    a, b, c (Å) 84.92 116.74 179.34  
 
()  90.00 94.29 90.00  
 
Wavelength (Å) 1.03 
Resolution (Å) 178.84-2.78 (2.83-
2.78)a 
Rmerge  8.5 (122.4)              
I/(I) 13.0 (1.4) 
CC1/2
 99.9 (59.4)            
Completeness (%) 99.9 (99.8) 
Redundancy 6.7 (6.8)             
  
Refinement  
Resolution (Å) 178.84 (2.78) 
No. reflections 83545 
Rwork / Rfree 20.6/24.5 
No. atoms  
    Protein 16722 
    Ligand/ion 6 
    Water 30 
B factors  
    Protein 80.8 
    Ligand/ion 81.6 
    Water 70.9 
R.m.s. deviations  
    Bond lengths (Å) 0.01 
    Bond angles () 1.8 
Single crystals were used for structure determination. 516 
aValues in parentheses are for highest-resolution shell. 517 
  518 
  519 
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